• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Working to Address Unmet Medical Needs in MPNs

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital. Read More

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery. Read More

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis. Read More

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. Read More

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group’s dose-limiting toxicity observation period was successfully completed. Read More

Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing research to improve patient outcomes. Read More
« Older Entries
Next Entries »

Recent Content

  • FDA speeds development of oral pancreatic cancer treatment
  • (no title)
  • (no title)
  • Oral safusidenib begins trial as maintenance for high-grade glioma
  • Outcomes of relapse after teclistamab therapy in multiple myeloma
  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT